@article{oai:jichi-ir.repo.nii.ac.jp:00000863,
 author = {Yamauchi, Tomohiko and Utano, Kenichi and Tsunoda, Saburo and Yokoyama, Shuji and Ogawa, Hiroshi},
 journal = {自治医科大学紀要, Jichi Medical University Journal},
 month = {Mar},
 note = {A 74-year-old man with refractory epistaxis and melena was diagnosed with hereditary hemorrhagic telangiectasia （HHT）. Frequent epistaxis required gauze packing, electrocautery, and blood transfusion. Ileocecal resection did not reduce melena. To control both epistaxis and melena, off-label administration of bevacizumab was planned and approved by the ethical committee at Fukushima Medical University. However, after three courses of low-dose bevacizumab （2 mg/kg, every 3 weeks）, the frequency of epistaxis and melena were not reduced. Thus, bevacizumab administration was discontinued.},
 pages = {19--23},
 title = {Low-dose bevacizumab did not reduce epistaxis in patient with hereditary hemorrhagic telangiectasia : a case report},
 volume = {42},
 year = {2020}
}